NeRRe Therapeutics CEO, Dr Mary Kerr, will present at BioTrinity 2017, May 9th, London, UK, The title of the presentation is “NeRRe Therapeutics – a unique Neurokinin antagonist pipeline with the potential to return significant near-term value”

NeRRe Therapeutics CEO, Dr Mary Kerr, will present at BioTrinity 2017, May 9th, London, UK, The title of the presentation is “NeRRe Therapeutics – a unique Neurokinin antagonist pipeline with the potential to return significant near-term value”